LI-RADS治疗反应算法对肝细胞癌的诊断效能:MRI辅助特征与CT和MRI强化模式的比较
本回顾性研究纳入2014年1月至2017年12月接受局部区域治疗后行手术切除或肝移植的肝细胞癌患者138例,评估在LI-RADS治疗反应算法基础上添加MRI辅助特征进行类别调整,与单独使用CT和钆塞酸增强MRI强化模式相比,对病理肿瘤活性的诊断效能;结果显示MRI辅助特征调整后敏感度提高而特异度无变化。
要点
- 在LI-RADS治疗反应算法中加入MRI辅助特征进行类别调整,可提高预测病理肿瘤活性的敏感度(84% vs CT 73%、MRI 76%),特异度无显著差异。
- 单独使用CT或MRI的LR-TR存活类别在预测肿瘤活性时敏感度和特异度均无显著差异(P=.65和P=.63)。
- MRI辅助特征调整后的特异度为80%,与CT的90%和MRI的83%相比无统计学差异(P=.38和P>.99)。
核心结论
- 在肝细胞癌患者中,将MRI辅助特征应用于LI-RADS治疗反应算法进行类别调整,与单独使用CT或MRI强化模式相比,预测病理肿瘤活性的敏感度更高且特异度不变。
研究设计与样本
- 回顾性研究,纳入2014年1月至2017年12月接受局部区域治疗后行手术切除或肝移植的肝细胞癌患者138例(138个治疗观察灶),所有患者均行局部区域治疗后CT和钆塞酸增强MRI检查;由三位放射科医生共识阅读,分别根据CT和MRI的LR-TR算法以及允许MRI辅助特征进行类别调整的MRI改良TR算法分配治疗反应类别;以病理肿瘤活性为参考标准。
诊断标准与关键数值
- CT LR-TR存活类别的敏感度为73%(79/108,95%CI:64%,81%),特异度为90%(27/30,95%CI:74%,98%);MRI LR-TR存活类别的敏感度为76%(82/108,95%CI:67%,84%),特异度为83%(25/30,95%CI:65%,94%);MRI改良TR存活类别的敏感度为84%(91/108,95%CI:76%,91%),特异度为80%(24/30,95%CI:61%,92%)。
临床应用与阅片要点
- 作者结论认为,在肝细胞癌局部区域治疗后的反应评估中,将MRI辅助特征应用于LI-RADS治疗反应算法进行类别调整,与单独使用CT或MRI强化模式相比,可提高预测病理肿瘤活性的敏感度且特异度不变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The Liver Imaging Reporting and Data System Treatment Response (LR-TR) algorithm is used to assess the response of hepatocellular carcinoma (HCC) to local-regional therapy (LRT) based on enhancement patterns. The potential value of adding MRI ancillary features (AFs) needs to be investigated. Purpose To evaluate the potential application of MRI AFs in category adjustment to detect pathologic tumor viability in comparison with the LR-TR algorithm in CT and gadoxetic acid-enhanced MRI. Materials and Methods This retrospective study included patients with HCCs treated with LRT followed by surgical resection or liver transplantation between January 2014 and December 2017 who underwent both post-LRT CT and gadoxetic acid-enhanced MRI. For each treated observation, treatment response (TR) categories were assigned based on a consensus reading of three radiologists according to the LR-TR algorithm in CT and MRI and according to the MRI-modified TR algorithm in which MRI AFs were allowed for category adjustment. The diagnostic performances of CT LR-TR viable, MRI LR-TR viable, and MRI-modified TR viable categories were compared intraindividually with the McNemar test, with pathologic tumor viability used as a reference standard. Results A total of 138 patients (119 men; mean age, 58 years ± 9 [standard deviation]) with 138 treated observations (108 pathologically viable) were evaluated. The sensitivity and specificity of CT LR-TR viable and MRI LR-TR viable categories for predicting tumor viability were 73% (79 of 108 lesions; 95% confidence interval [CI]: 64%, 81%) versus 76% (82 of 108 lesions; 95% CI: 67%, 84%) and 90% (27 of 30 lesions; 95% CI: 74%, 98%) versus 83% (25 of 30 lesions; 95% CI: 65%, 94%), respectively, without differences between CT and MRI (P = .65 and P = .63, respectively). MRI-modified TR viable category had higher sensitivity (84% [91 of 108 lesions; 95% CI: 76%, 91%]) than CT or MRI LR-TR viable category (P = .002 and P = .01, respectively), without difference in specificity (80% [24 of 30 lesions]; 95% CI: 61%, 92%) (P = .38 and P > .99, respectively). Conclusion The application of MRI ancillary features to the Liver Imaging Reporting and Data System Treatment Response algorithm resulted in higher sensitivity and no change in specificity compared with CT or MRI enhancement patterns alone in the prediction of pathologic tumor viability in patients with hepatocellular carcinoma. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Do and Mendiratta-Lala in this issue.
引用
- Park S, Joo I, Lee DH, et al. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI. Radiology. 2020. PMID: 32692297. doi:10.1148/radiol.2020192797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。